A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1126-1131

  Advani, Anjali ^a   Jin, Tao ^b   Bolwell, Brian ^a   Copelan, Edward ^a   Sekeres, Mikkael ^a   Sobecks, Ronald ^a   Sungren, Shawnda ^a   Yurch, Melissa ^a   Kalaycio, Matt ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Bone marrow transplant; Lactate dehydrogenase; Prognosis; Relapse

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BUSULFAN; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMATINIB; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CYTOGENETICS; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68549125320     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902962838     Document Type: Article

References (10)

1. Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol 2006;18:652-659.
2. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): An MRCUKALL12/ECOG2993 study.Blood 2007;109:944-950.
3. Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007;82:1063-1070.
4. Keating MJ, Kantarjian H, Smith TL, et al. Salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7:1071-1080.
5. Hoelzer D, Theil E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-131.
6. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience. Blood 1999;93:3983-3993.
7. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091-2097.
8. Wiernik PH, Dutcher JP, Paietta E, et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD, a non-anthracycline-containing regimen. Leukemia 1993;7:1236-1241.
9. Csako G, Magrath IT, Elin RJ. Serum total and isoenzyme lactate dehydrogenase activity in American Burkitt's lymphoma patients. Am J Clin Pathol 1982;78:712-717.
10. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from matched sibling allogeneic transplantation in first complete remission, and autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993). Blood 2008;111:1827-1833.